PL2568980T3 - Pasożytobójcze preparaty lewamizolu i laktonów makrocyklicznych do wstrzykiwania - Google Patents

Pasożytobójcze preparaty lewamizolu i laktonów makrocyklicznych do wstrzykiwania

Info

Publication number
PL2568980T3
PL2568980T3 PL11731566T PL11731566T PL2568980T3 PL 2568980 T3 PL2568980 T3 PL 2568980T3 PL 11731566 T PL11731566 T PL 11731566T PL 11731566 T PL11731566 T PL 11731566T PL 2568980 T3 PL2568980 T3 PL 2568980T3
Authority
PL
Poland
Prior art keywords
levamisole
macrocyclic lactones
parasiticidal formulations
injectable
injectable parasiticidal
Prior art date
Application number
PL11731566T
Other languages
English (en)
Inventor
Robert Holmes
Majid Razzak
Alan Johnson
Jitendra Goswami
Atul Awasthi
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44342950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2568980(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Inc filed Critical Merial Inc
Publication of PL2568980T3 publication Critical patent/PL2568980T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
PL11731566T 2010-05-12 2011-05-12 Pasożytobójcze preparaty lewamizolu i laktonów makrocyklicznych do wstrzykiwania PL2568980T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33388210P 2010-05-12 2010-05-12
EP11731566.3A EP2568980B1 (en) 2010-05-12 2011-05-12 Injectable parasiticidal formulations of levamisole and macrocyclic lactones
PCT/US2011/036321 WO2011143479A1 (en) 2010-05-12 2011-05-12 Injectable parasiticidal formulations of levamisole and macrocyclic lactones

Publications (1)

Publication Number Publication Date
PL2568980T3 true PL2568980T3 (pl) 2016-05-31

Family

ID=44342950

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11731566T PL2568980T3 (pl) 2010-05-12 2011-05-12 Pasożytobójcze preparaty lewamizolu i laktonów makrocyklicznych do wstrzykiwania

Country Status (13)

Country Link
US (1) US20110281920A1 (pl)
EP (1) EP2568980B1 (pl)
AR (1) AR081187A1 (pl)
AU (1) AU2011252987B2 (pl)
DK (1) DK2568980T3 (pl)
ES (1) ES2554245T3 (pl)
HR (1) HRP20160103T1 (pl)
HU (1) HUE028600T2 (pl)
NZ (1) NZ603699A (pl)
PL (1) PL2568980T3 (pl)
PT (1) PT2568980E (pl)
SI (1) SI2568980T1 (pl)
WO (1) WO2011143479A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010101389C4 (en) * 2010-12-08 2017-03-02 Jurox Pty Ltd Anthelmintic formulation
CA2839491A1 (en) * 2011-06-23 2012-12-27 Bayer New Zealand Limited Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation
NZ594610A (en) * 2011-08-16 2013-03-28 Virbac New Zealand Ltd Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
US20140045885A1 (en) * 2012-08-10 2014-02-13 Siobhan P. Ellison Decoquinate, 4-hydroxyquinolones and napthoquinones combined with levamisole, Imidazothiazole, for the prevention and treatment of sarcocystosis and equine protozoal myeloencephalitis caused by Sarcocystis and Neospora and other apicomplexan protozoans.
RU2527329C2 (ru) * 2012-10-25 2014-08-27 Государственное научное учреждение Курский научно-исследовательский институт агропромышленного производства Россельхозакадемии Способ получения комплексного иммунометаболического препарата с антиинфекционной активностью
WO2014098623A1 (en) * 2012-12-20 2014-06-26 Alleva Animal Health Limited Injectable eprinomectin formulation and anthelmintic use thereof
NZ712345A (en) 2013-04-12 2016-04-29 Zoetis Services Llc Composition of macrocyclic lactones, levamisole, an amino sugar and an additional antiparasitic agent
BR102013031277B1 (pt) * 2013-12-05 2018-10-02 Ouro Fino Participacoes E Empreendimentos S A processo para preparar uma suspensão anti-helmíntica e suspensão anti-helmíntica injetável
AU2016200283B2 (en) * 2015-02-21 2016-10-13 Al Hanbali, Othman Abdul Rahim DR LEVIA: A New Injectable Parasiticidal Veterinary Formulation of Levamisole HCI and Ivermectin Solution
WO2018038623A1 (en) * 2016-08-23 2018-03-01 Donaghys Limited Improvements in parasite treatments

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4096271A (en) * 1977-08-03 1978-06-20 American Cyanamid Company Slow release injectable formulations of tetramisole and derivatives in benzyl benzoate
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4389397A (en) * 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
US4427663A (en) 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
EP0237482A1 (de) 1986-03-06 1987-09-16 Ciba-Geigy Ag C(29)-Carbonyloxi-milbemycin-Derivate zur Bekämpfung von tier- und pflanzenparasitären Schädlingen
EP0246739B1 (en) 1986-03-25 1991-01-23 Sankyo Company Limited Macrolide compounds, their preparation and their use
DE3778768D1 (de) 1986-07-02 1992-06-11 Ciba Geigy Ag Pestizide.
US4855317A (en) 1987-03-06 1989-08-08 Ciba-Geigy Corporation Insecticides and parasiticides
US4871719A (en) 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4874749A (en) 1987-07-31 1989-10-17 Merck & Co., Inc. 4"-Deoxy-4-N-methylamino avermectin Bla/Blb
EP0319142B1 (en) 1987-11-03 1994-04-06 Beecham Group Plc Intermediates for the preparation of anthelmintic macrolide antibiotics
NZ232422A (en) 1989-02-16 1992-11-25 Merck & Co Inc 13-ketal milbemycin derivatives and parasiticides
US5602107A (en) 1993-05-10 1997-02-11 Merck & Co., Inc. Pour-on formulations consisting of gylcols, glycerides and avermectin compounds
US6733767B2 (en) 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
AR035550A1 (es) * 1999-06-04 2004-06-16 Nufarm Ltd Composiciones estables biocidas
CR6574A (es) 2001-02-27 2004-10-28 Syngenta Participations Ag Sales de avermectinas substituidas en la posicion 4 con propiedades plaguicidas
EG23124A (en) 2001-02-27 2004-04-28 Syngenta Participations Ag Avermectins substituted in the 4-position having pesticidal properties
AR036486A1 (es) 2001-08-28 2004-09-15 Syngenta Participations Ag Derivados 4"-desoxi-4"-(s)-amino avermectina, composicion plaguicida, procedimiento para la preparacion de esa composicion, metodo para controlar plagas, y uso de estos derivados para preparar una composicion
AR037938A1 (es) 2001-12-21 2004-12-22 Syngenta Participations Ag Derivados de avermectina b1 que tienen un substituyente de aminosulfoniloxilo en la posicion 4''
NZ520295A (en) * 2002-07-19 2005-04-29 Ashmont Holdings Ltd Anthelmintic formulations comprising levamisole and either an avermectin or milbemycin
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
GB0302310D0 (en) 2003-01-31 2003-03-05 Syngenta Participations Ag Avermectin- and avermectin monosaccharide derivatives substituted in the 4"- or 4' - positionhaving pesticidal properties
GB0302308D0 (en) 2003-01-31 2003-03-05 Syngenta Participations Ag Avermectin and avermectin monosaccharide derivatives substituted in the 4"- or 4'-position having pesticidal properties
AU2003900505A0 (en) * 2003-02-05 2003-02-20 Jurox Pty Ltd Anthelmintic composition
GB0313937D0 (en) 2003-06-16 2003-07-23 Syngenta Participations Ag Avermectin B1 monosaccharide derivatives having an aminosulfonyloxy substituentin the 4'-position
GB0320176D0 (en) 2003-08-28 2003-10-01 Syngenta Participations Ag Avermectins and avermectin monosaccharides substitued in the 4'-and 4"-positionhaving pesticidal properties
WO2005120585A1 (en) * 2004-06-04 2005-12-22 Case Western Reserve University Dual function polymer micelles
CN101065352A (zh) * 2004-09-23 2007-10-31 先灵-普劳有限公司 使用新的三氟甲磺酰苯胺肟醚衍生物控制动物中的寄生虫
BRPI0506279B1 (pt) 2005-12-16 2018-01-09 Npa - Núcleo De Pesquisas Aplicadas Ltda Composição sinergística de antihelmínticos e endectocidas
US8399442B2 (en) * 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
CA2734459A1 (en) 2008-08-18 2010-02-25 Intervet International B.V. Anthelmintic compositions
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same

Also Published As

Publication number Publication date
ES2554245T3 (es) 2015-12-17
WO2011143479A1 (en) 2011-11-17
US20110281920A1 (en) 2011-11-17
SI2568980T1 (sl) 2016-02-29
AU2011252987A1 (en) 2012-12-13
AU2011252987B2 (en) 2013-05-02
EP2568980A1 (en) 2013-03-20
NZ603699A (en) 2013-08-30
AR081187A1 (es) 2012-07-04
HRP20160103T1 (hr) 2016-02-26
HUE028600T2 (en) 2016-12-28
DK2568980T3 (en) 2015-11-30
EP2568980B1 (en) 2015-11-11
PT2568980E (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
SI2568980T1 (sl) Injekcijske paraziticidne formulacije levamizola in makrocikličnih laktonov
HK1217287A1 (zh) 活性物質的凍干組合物
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
ZA201300193B (en) Formulations of rifaximin and uses thereof
EP2624834A4 (en) LACTONE-BASED MACROCYCLIC COMPOUNDS AND METHODS OF USE
EP2637655A4 (en) PHARMACEUTICAL COMPOSITION OF TAXOIDES
EP2627391A4 (en) HYDROPHOBIC CATHETER AND COMPOSITION
ZA201209445B (en) Injectable formulation of a macrocyclic lactone and levamisole
ZA201304214B (en) Lactone compounds and materials made therefrom
IL224191A (en) Compositions of vitamin d and cmc epi-14 analogues
ZA201208473B (en) Epoxidation of glycerol and derivatives therefrom
PL2585041T3 (pl) Preparat farmaceutyczny o zamaskowanym smaku o przyspieszonym początku działania
EP2544683A4 (en) SYNERGISTIC EFFECT OF TOCOTRIENOLS AND CURCUMIN
EP2723335A4 (en) ANTIPARASITIC COMPOSITION COMPRISING MACROCYCLIC LACTONE AND LEVAMISOLE AND METHOD OF TREATING PARASITIC INFESTATION
PL2407159T3 (pl) Kompozycje farmaceutyczne olmesartanu
EP2629772A4 (en) METHOD FOR THE TREATMENT OF HERPESVIRUS INFECTIONS USING A MACROCYCLIC LACTON COMPOUND
EP2874624B8 (en) Injectable antibiotic formulations and their methods of use
ZA201209745B (en) Compositions containing flavones and anthelmintics
EP2574194A4 (en) MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT
EP2874623A4 (en) INJECTABLE ANTIBIOTIC FORMULATIONS AND METHODS OF USE
TWM390994U (en) Structure of rolling door
TWM402708U (en) Structure of coffin
TWM402707U (en) Structure of coffin
TWM385337U (en) Improved structure of urn
EP2415465A4 (en) STABILIZATION-FREE PHARMACEUTICAL TETRAHYDROLIPSTATINE COMPOSITIONS